Hydrochlorothiazide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 99: | Line 99: | ||
* Dosing Information | * Dosing Information | ||
:* 0.5–2 mg/kg/day<ref>{{Cite journal | issn = 0022-5347 | volume = 128 | issue = 5 | pages = 903–907 | last = Scholz | first = D. | coauthors = P. O. Schwille, A. Sigel | title = Double-blind study with thiazide in recurrent calcium lithiasis | journal = The Journal of Urology | date = 1982-11 | pmid = 7176047 }}</ref> | :* '''0.5–2 mg/kg/day'''<ref>{{Cite journal | issn = 0022-5347 | volume = 128 | issue = 5 | pages = 903–907 | last = Scholz | first = D. | coauthors = P. O. Schwille, A. Sigel | title = Double-blind study with thiazide in recurrent calcium lithiasis | journal = The Journal of Urology | date = 1982-11 | pmid = 7176047 }}</ref> | ||
=====Bronchopulmonary Dysplasia of Newborn===== | =====Bronchopulmonary Dysplasia of Newborn===== | ||
| Line 105: | Line 105: | ||
* Dosing Information | * Dosing Information | ||
:* 1 mg/kd/day<ref>{{Cite journal | issn = 0022-3476 | volume = 115 | issue = 4 | pages = 615–620 | last = Albersheim | first = S. G. | coauthors = A. J. Solimano, A. K. Sharma, J. A. Smyth, A. Rotschild, B. J. Wood, S. B. Sheps | title = Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia | journal = The Journal of Pediatrics | date = 1989-10 | pmid = 2677293 }}</ref> | :* '''1 mg/kd/day'''<ref>{{Cite journal | issn = 0022-3476 | volume = 115 | issue = 4 | pages = 615–620 | last = Albersheim | first = S. G. | coauthors = A. J. Solimano, A. K. Sharma, J. A. Smyth, A. Rotschild, B. J. Wood, S. B. Sheps | title = Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia | journal = The Journal of Pediatrics | date = 1989-10 | pmid = 2677293 }}</ref> | ||
<!--Contraindications--> | <!--Contraindications--> | ||
Revision as of 23:38, 6 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Hydrochlorothiazide is a thiazide diuretic that is FDA approved for the {{{indicationType}}} of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Common adverse reactions include hypotension, phototoxicity, and vertigo.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Hypertension
- Dosing Information
- 12.5 mg once daily whether given alone or in combination with other antihypertensives.
- Total daily doses greater than 50 mg are not recommended.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Hydrochlorothiazide in adult patients.
Non–Guideline-Supported Use
Hypercalciuria
- Dosing Information
Osteoporosis
- Dosing Information
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Hydrochlorothiazide in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Hydrochlorothiazide in pediatric patients.
Non–Guideline-Supported Use
Hypercalciuria
- Dosing Information
- 0.5–2 mg/kg/day[8]
Bronchopulmonary Dysplasia of Newborn
- Dosing Information
- 1 mg/kd/day[9]
Contraindications
- Condition1
Warnings
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Hydrochlorothiazide in the drug label.
Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Hydrochlorothiazide in the drug label.
Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Hydrochlorothiazide in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Hydrochlorothiazide during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Hydrochlorothiazide with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Hydrochlorothiazide with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Hydrochlorothiazide with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Hydrochlorothiazide with respect to specific gender populations.
Race
There is no FDA guidance on the use of Hydrochlorothiazide with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Hydrochlorothiazide in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Hydrochlorothiazide in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Hydrochlorothiazide in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Hydrochlorothiazide in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Hydrochlorothiazide in the drug label.
Condition1
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Hydrochlorothiazide in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Hydrochlorothiazide in the drug label.
Pharmacology
Mechanism of Action
Structure
This image is provided by the National Library of Medicine.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Hydrochlorothiazide in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Hydrochlorothiazide in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Hydrochlorothiazide in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Hydrochlorothiazide in the drug label.
Condition1
- Description
How Supplied
Storage
There is limited information regarding Hydrochlorothiazide Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Hydrochlorothiazide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Hydrochlorothiazide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Hydrochlorothiazide in the drug label.
Precautions with Alcohol
- Alcohol-Hydrochlorothiazide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- Microzide®[11]
Look-Alike Drug Names
- Microzide® — Maxzide®[12]
- Microzide® — Micronase®[12]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ Scholz, D. (1982-11). "Double-blind study with thiazide in recurrent calcium lithiasis". The Journal of Urology. 128 (5): 903–907. ISSN 0022-5347. PMID 7176047. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ Laerum, E. (1984). "Metabolic effects of thiazide versus placebo in patients under long-term treatment for recurrent urolithiasis". Scandinavian Journal of Urology and Nephrology. 18 (2): 143–149. ISSN 0036-5599. PMID 6463598.
- ↑ Laerum, E. (1984). "Thiazide prophylaxis of urolithiasis. A double-blind study in general practice". Acta Medica Scandinavica. 215 (4): 383–389. ISSN 0001-6101. PMID 6375276. Unknown parameter
|coauthors=ignored (help) - ↑ Bentur, L. (1987-03). "Hypercalciuria in chronically institutionalized bedridden children: frequency, predictive factors and response to treatment with thiazides". The International Journal of Pediatric Nephrology. 8 (1): 29–34. ISSN 0391-6510. PMID 3583554. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ Wasnich, R. D. (1986-04). "Differential effects of thiazide and estrogen upon bone mineral content and fracture prevalence". Obstetrics and Gynecology. 67 (4): 457–462. ISSN 0029-7844. PMID 3960416. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ Ray, W. A. (1989-04-01). "Long-term use of thiazide diuretics and risk of hip fracture". Lancet. 1 (8640): 687–690. ISSN 0140-6736. PMID 2564506. Unknown parameter
|coauthors=ignored (help) - ↑ LaCroix, A. Z. (2000-10-03). "Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial". Annals of Internal Medicine. 133 (7): 516–526. ISSN 0003-4819. PMID 11015164. Unknown parameter
|coauthors=ignored (help) - ↑ Scholz, D. (1982-11). "Double-blind study with thiazide in recurrent calcium lithiasis". The Journal of Urology. 128 (5): 903–907. ISSN 0022-5347. PMID 7176047. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ Albersheim, S. G. (1989-10). "Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia". The Journal of Pediatrics. 115 (4): 615–620. ISSN 0022-3476. PMID 2677293. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ Beermann B, Groschinsky-Grind M, Rosén A. (1976). "Absorption, metabolism, and excretion of hydrochlorothiazide". Clin Pharmacol Ther. 19 (5 (Pt 1)): 531–7.
- ↑ "MICROZIDE (hydrochlorothiazide) capsule, gelatin coated".
- ↑ 12.0 12.1 "http://www.ismp.org". External link in
|title=(help)
{{#subobject:
|Page Name=Hydrochlorothiazide |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage= |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Hydrochlorothiazide |Label Name=Hydrochlorothiazide02.png
}}
{{#subobject:
|Label Page=Hydrochlorothiazide |Label Name=Hydrochlorothiazide03.png
}}